Clinical trials: sponsored by Sanofi
Healthy Volunteers
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants
This is a Phase 1 study with 2 parallel groups of healthy participants. Participants will be randomized to receive either a subcutaneous (SC) dose of dupilumab coformulated with berahyaluronidase alfa or a SC dose of dupilumab…
- Trial name
- NCT07646548
- Testing
- Dupilumab coformulated with berahyaluronidase alfa, Dupilumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hidradenitis, Healthy Volunteers
SAR447971 First-in-human Study
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.
- Trial name
- NCT07629336
- Testing
- SAR447971
- Where
- Netherlands
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 1 Diabetes
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D.
- Trial name
- NCT07038473
- Testing
- Investigational Procedure
- Where
- 7 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Renal Impairment, Healthy Volunteers
Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function
The purpose of this Phase 1, open-label, 2-arm study is to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75…
- Trial name
- NCT07853131
- Testing
- rilzabrutinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sanofi
Immunization, Healthy Volunteers
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60…
- Conditions
- Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
- Trial name
- NCT07890454
- Testing
- IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteer
An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition
The study is a single-center, Phase-1, open-label, one-sequence, two-treatment period, cross-over, DDI study designed to investigate the effects of rilzabrutinib on the PK of digoxin (as P-gp substrate) and of rosuvastatin (as…
- Trial name
- NCT07855250
- Testing
- Rilzabrutinib, Rosuvastatin, Digoxin
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza Immunization, Healthy Volunteers
Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
To objective of this study is to investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda® in adults aged 65 years or older under routine clinical practice…
- Trial name
- NCT07282795
- Testing
- Efluelda® Pre-filled syringe
- Where
- 15 sites in South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Sanofi
Meningococcal Infection, Healthy Volunteers
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China
The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.
- Trial name
- NCT07710872
- Testing
- MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA), Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)
- Where
- 8 sites in China
- Volunteers
- 4,568 people, healthy volunteers welcome
- Sponsor
- Sanofi
Respiratory Syncytial Virus, Human Metapneumovirus
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy…
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers
- Trial name
- NCT07810010
- Testing
- Bivalent RSV+HMPV protein vaccine
- Where
- 21 sites in Australia, United Kingdom
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
Meningococcal Infection, Healthy Volunteers
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and…
- Trial name
- NCT07135986
- Testing
- MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine
- Where
- 4 sites in China
- Volunteers
- 1,602 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at…
- Trial name
- NCT07861542
- Testing
- Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M
- Where
- 20 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Sanofi
RSV Immunization
RSV Immunisation Status in Queensland (Australia)
The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia.
- Trial name
- NCT07615192
- Testing
- Nirsevimab Respiratory Syncytial Virus monoclonal antibody
- Where
- Australia
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- Sanofi
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older.
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Trial name
- NCT07734649
- Testing
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4
- Where
- 50 sites in United States
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi
Yellow Fever Immunization
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
The purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and…
- Trial name
- NCT07103148
- Testing
- Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated
- Where
- 15 sites in Honduras, Mexico and 1 more
- Volunteers
- 2,440 people, healthy volunteers welcome
- Sponsor
- Sanofi
Meningococcal Immunisation, Healthy Volunteers
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers
This study was conducted to support a 2-dose series (1+1 vaccination schedule) for immunization of individuals from 6 months of age.
- Trial name
- NCT06284915
- Testing
- MenACYW conjugate vaccine
- Where
- 45 sites in Czechia, Denmark and 4 more
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
RSV Immunization
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12…
- Trial name
- CORAL (NCT06397768)
- Testing
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine
- Where
- 72 sites in United States, Mexico and 1 more
- Volunteers
- 2,226 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Immunization, Healthy Volunteers
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies"…
- Trial name
- NCT07348692
- Testing
- PCV21 vaccine, 20vPCV licensed vaccine
- Where
- 25 sites in United States, Honduras and 2 more
- Volunteers
- 2,195 people, healthy volunteers welcome
- Sponsor
- Sanofi
Cancer, Neoplasm
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
The study enrolled advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy.
- Trial name
- NCT04717375
- Testing
- SAR444881, Pembrolizumab, Cetuximab
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sanofi
Eosinophilic Esophagitis
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with…
- Trial name
- ProMEAL (NCT06695897)
- Testing
- Dupilumab
- Where
- 15 sites in Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers, Influenza
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness.
- Trial name
- NCT07779408
- Testing
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Where
- 16 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi